Le LÚzard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after the market closes on Thursday, November 5, 2020.

Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 7307079. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. The webcast will be archived on the company website for 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor's XmAb« technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.


These press releases may also interest you

at 21:30
The global organization Mercy Corps has reached more than 15.1 million people, addressing both the immediate and long-term impact of COVID-19. Since launching the COVID-19 Resilience Fund in mid-April, the organization has raised over $60.5 million...

at 21:00
100x Group, the holding group for HDR Global Trading Limited, owner and operator of the BitMEX platform, has appointed Alexander H÷ptner as its new Chief Executive Officer. á H÷ptner will lead 100x Group asáthey pursue their vision of shaping the...

at 20:50
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew...

at 20:45
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew...

at 20:35
Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocyte spheroids for the treatment of heart failure (hereinafter HF), today announced that they have been named 2020 Healthcare Company of the...

at 20:25
In June 2020, a consortium has been initiated by InnoStudio Inc. (HU) for the development and validation of highly efficient active compounds against SARS-CoV-2 while conducting drug discovery simultaneously and in a synchronized manner in space and...



News published on 29 october 2020 at 16:05 and distributed by: